Biogen Dividend yield

 Price  195.38
 Dividend  0.00
 Earnings  12.37
 Cash-flow  24.73
 Book value  75.15
 Equity  74.07

Biogen is part of Pharmaceuticals and Biotechnology business, which is part of Health Care industry. Biogen is a company from USA, and his stocks are publicly traded.

Biogen paid a total dividend of 0 million USD last year, for a market value of 28,721 millions (Market Cap 28,431 millions). Dividend per share of Biogen is 0.00 USD, and his stock market price 195.38 USD.

According to the chart below where dividend yield is displayed, Biogen, has a dividend yield of 0%, amount in contrast with the positive dividend offered by both the market average and companies from USA, Health Care industry, and Pharmaceuticals and Biotechnology sector. This lack of dividends of Biogen might harm the evolution of share price if the company is not clearly expanding his business.

In addition, you should compare Biogen dividend yield with other Pharmaceuticals and Biotechnology companies or firms from USA.

Dividend yield of Biogen

Biogen Dividend Payout

About the ability of Biogen to maintain his current dividend of USD 0.00 per share, an amount that accounts for 0.00%, we should study its payout ratio both on earnings and on cash-flows (see chart below). Biogen payout on ernings is currently 0.00%, which is lower than the market average and companies in his industry and sector.

The following figure shows payout ratios over earnings and cashflow of Biogen, compared againt world market average, USA companies, Health Care industry and Pharmaceuticals and Biotechnology sector companies.

Biogen payout

Biogen Dividend History

Year Yield  USD  Paypout  Shares* 

*In millions

Biogen Stock performance

Finally, last moth Biogen showed a return of -9.20% compared to a worldwide -0.44% average, and a -4.27% of Health Care firms. Over the last year, the company obtained a -42.40% versus a worldwide performance of a -6.34%. More detailed information can be seen in the following graph for USA and Pharmaceuticals and Biotechnology firms.

Biogen stock and market return